TP53 and hyperinsulinemic hypoglycemia, familial, 4: Clinically these mutations could already be actionable, as TP53 mutations are a sign of DNA damage repair deficiency and may be prognostic for sensitivity to PARP inhibition (Holstege et al, 2010; Severson et al, 2015).